Adherence to Artemisinin-Based Combination Therapy for the Treatment of Uncomplicated Malaria: A Systematic Review and Meta-Analysis

Table 3

ACT recommended in different countries [7].

Continent	ACT recommended	Countries
Africa	AL	Angola, Benin, Burkina Faso, CAR, Chad, Comoros, Ethiopia, South Africa, Tanzania, Togo, Zambia, Zimbabwe, Côte d’Ivoire, Djibouti, Gabon, Malawi, Mozambique, Sudan (N), Sao Tome and Principe, and Tanzania
	AS/AQ	Burundi, Cameroon, Côte d’Ivoire, Democratic Republic of the Congo, Equatorial Guinea Gabo, Ghana, Liberia, Madagascar, Malawi, Mauritania, Senegal, Sao Tome and Principe, Sierra Leone, Sudan (S), and Tanzania
	AS/SP	Mozambique, Djibouti, Somalia, South Africa, and Sudan (N)
Asia	AS/MQ	Cambodia, Malaysia, Myanmar, and Thailand
	AL	Bangladesh, Bhutan, Laos, and Saudi Arabia
	AS/AQ	Indonesia
	AS/SP	Afghanistan, India, Iran, Tajikistan, Yemen, and Papua New Guinea
	DP	Vietnam
	AL	Iran, Philippines, and Solomon Islands
South America	AS/SP	Ecuador, Peru
	AS/MQ	Bolivia, Peru, and Venezuela
	AL	Brazil, Guyana, and Suriname

AL: artemether-lumefantrine, AQ: amodiaquine, AS: artesunate, DA/PQ: dihydroartemisinin/piperaquine, MQ: mefloquine, and SP: sulphadoxine-pyrimethamine.